Investor Relations | CHUGAI PHARMACEUTICAL CO., LTD.

Home > Investor Relations

2018 1Q Results (Jan-Mar 2018) Conference Call

Apr 24, 2018

Jun 05: Webcast of Information Meeting on HEMLIBRA^®
Jun 01: Information Meeting on HEMLIBRA®
Jun 01: CEO Message Video "The Relentless Pursuit of Innovation"
May 24: Webcast of R&D Conference Call (WFH 2018)
May 22: R&D Conference Call (WFH 2018)

More

Jun 05

Chugai’s HEMLIBRA® Receives Priority Review Status from U.S. FDA for Hemophilia A without Inhibitors
- Second Designation following Hemophilia A with inhibitors -

[

PDF 134KB]

May 29

Humanized Anti-Human IL-6 Receptor Monoclonal Antibody “ACTEMRA^®,”
Application for Approval of Additional Indication of Cytokine Release Syndrome Induced by Treatment with CAR-T Cell Therapy

[

PDF 57KB]

May 24

Humanized Anti-Human IL-6 Receptor Monoclonal Antibody “ACTEMRA^®,” Application for Approval of Additional Indication of Adult Onset Still's Disease

[

PDF 51KB]

May 22

Launch of HEMLIBRA® Subcutaneous Injection for the Treatment of Hemophilia A

[

PDF 154KB]

May 21

Chugai Presents Results of Two Pivotal Phase III Studies
for its Bispecific Antibody HEMLIBRA® at WFH 2018

[

PDF 215KB]

More

Management Policy

TSE Code:4519

Share Graph

Annual Report 2017 (Integrated Edition Including CSR Report)
[ 6.1MB]

Supplementary Materials

Chugai Pharmaceutical Co., Ltd. takes great care over the information presented on this website, but it does not guarantee its accuracy, completeness, usefulness, etc. Furthermore, Chugai Pharmaceutical Co., Ltd. will not be responsible for any damages resulting from the use of this website or the information presented on this website. For further details, please read the following "Terms and Conditions of Website Use."

Copyright © Chugai Pharmaceutical Co., Ltd. All rights reserved.